After a dosing arm of a trial - normally a pharma doesn't need to go running to the FDA to move into the selected dose (even the trial protocol says that) - unless the FDA may have a problem with what you want to do.
Just saying.
Learn FDA protocol. And stop saying the drug impacts DNA because some non-medico private citizen of Otago, New Zealand said it in a discussion paper.
My conclusions are founded in a more robust inquiry.
After a dosing arm of a trial - normally a pharma doesn't need...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |